For decades, the idea of training the immune system to recognize and destroy a patient's own tumor has tantalized oncologists — yet only one therapeutic cancer vaccine has ever earned FDA approval. That stagnation may now be ending, and understanding why matters enormously for anyone tracking the frontier of cancer prevention and longevity medicine.
This comprehensive review, published in Signal Transduction and Targeted Therapy, maps the current landscape of personalized cancer vaccination across five platform classes: DNA-based, mRNA-based, peptide-based, dendritic cell-based, and whole-cell-based constructs. Central attention falls on two mRNA candidates — Moderna's mRNA-4157 (in combination with pembrolizumab) and BioNTech's autogene cevumeran — both of which have demonstrated statistically meaningful reductions in cancer recurrence and improvements in survival signals across multiple tumor types in clinical data. The review also details next-generation nanovaccine delivery systems, including lipid-polymer hybrids and biomimetic membranes derived from autologous tumor tissue, which improve lymph node targeting and dendritic cell activation. Artificial intelligence-assisted neoantigen selection is flagged as a critical enabler of individualized antigen prioritization at scale.
Putting this in context: personalized cancer vaccination sits at the intersection of two maturing fields — mRNA platform technology, validated by COVID-19 immunization at global scale, and computational immunogenomics, which can now identify patient-specific neoantigens far more reliably than a decade ago. The persistent barriers remain real: tumor heterogeneity means no single antigen profile captures every malignant cell, and immunosuppressive tumor microenvironments actively blunt vaccine-driven T-cell responses. This review is a synthesis rather than novel trial data, so its strength lies in analytical breadth rather than new efficacy numbers. Still, the convergence of AI-guided antigen selection, lipid nanoparticle delivery refinements, and checkpoint inhibitor combination strategies represents a genuinely different paradigm from earlier peptide vaccine failures. For longevity-focused readers, individualized cancer vaccines could eventually reframe early-stage malignancy as a manageable chronic immune challenge rather than an acute crisis — an incremental but directionally significant shift.